Grifols (GRFS) Selling, General & Administrative (2011 - 2018)
Grifols (GRFS) Selling, General & Administrative (2011 - 2018) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
SG&A (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
2.93 Bn |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
6.03 Bn |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
3.58 Bn |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
-4.92 Bn |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
2.70 Bn |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
1.60 Bn |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
1.45 Bn |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
2.96 Bn |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Grifols |
- |
- |
- |
- |
| Date | Value |
|---|
| Jun 30, 2018 |
235.65 Mn |
| Jun 30, 2017 |
235.06 Mn |
| Dec 31, 2016 |
1.45 Bn |
| Sep 30, 2016 |
196.59 Mn |
| Jun 30, 2016 |
222.32 Mn |
| Dec 31, 2015 |
222.71 Mn |
| Sep 30, 2015 |
201.39 Mn |
| Jun 30, 2015 |
208.17 Mn |
| Mar 31, 2015 |
-185.09 Mn |
| Dec 31, 2014 |
203.92 Mn |
| Sep 30, 2014 |
226.61 Mn |
| Jun 30, 2014 |
230,367.44 |
| Mar 31, 2014 |
217.83 Mn |
| Dec 31, 2013 |
203.07 Mn |
| Sep 30, 2013 |
182.22 Mn |
| Jun 30, 2013 |
180.81 Mn |
| Mar 31, 2013 |
175.97 Mn |
| Dec 31, 2012 |
189.38 Mn |
| Sep 30, 2012 |
163.37 Mn |
| Jun 30, 2012 |
175.55 Mn |
